Participating in a clinical trial can be both exciting and confusing, especially when considering the potential health impacts. Clinical trials are essential for determining the efficacy and safety of new treatments. Governing bodies oversee these trials, ensuring they meet strict standards to protect participants’ safety and ethical considerations.
While there are risks involved, particularly in early-phase trials, researchers take extensive precautions. They start with minimal doses of interventions, gradually increasing them to monitor for side effects. Despite public concerns, actual rates of side effects are typically lower than expected, though risks can increase when participants take multiple medications. It’s crucial to inform researchers of any existing prescriptions to avoid adverse interactions.
Informed consent is a vital part of clinical trials. Participants receive detailed information about the study and interventions, which helps them understand the risks and safety measures. This process includes a thorough discussion and documentation, allowing participants to ask questions and fully grasp the study’s implications.
Before joining a trial, potential participants undergo a rigorous screening process, including medical history reviews, physical exams, and various tests. This ensures that only suitable candidates participate, reducing the likelihood of negative reactions.
While there are inherent risks, the presence of regulatory bodies, comprehensive screening, and informed consent procedures significantly enhance the safety of clinical trials.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
